Skip to main content Skip to main navigation menu Skip to site footer

Clinicopathological and Prognostic Significance of SRY-Box Transcription Factor 2 (SOX2) Overexpression in Central Nervous System Tumor: A Meta-Analysis


Background: Central nervous system (CNS) tumors have been recognized as a type of tumor with high progressivity and a five-year survival rate of just 36%. SRY-related high mobility group box-2 (SOX2) is a gene encoding the Sox2 protein which is found to be overexpressed in various CNS tumors and contribute to its progressiveness. This gene contributes to CNS tumors through several signaling pathways, including Shh, Wnt, FGFR, and TGF-β signaling pathways. This meta-analysis aims to evaluate the clinicopathological and prognostic significance of SOX2 overexpression in CNS tumor.

Patients and methods: The literature searches on Cochrane Library, PubMed, and ScienceDirect were conducted systematically up to December 2022 based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) method to find relevant references. The effect of SOX2 overexpression on clinicopathological characteristics and prognostic value were analyzed using Review Manager 5.4 (Cochrane Collaboration, Oxford, UK).

Results: Ten suitable studies with a total of 466 patients with CNS tumors including gliomas (glioblastoma, astrocytoma, oligoastrocytoma, and oligodendrogliomas) and meningiomas, were included. Our analysis shows a significant association between the overexpression of SOX2 with the grade of CNS tumor (OR 7.05; 95%CI: 2.83 to 17.53; I2 = 53%; p< 0.0001) both in gliomas and meningiomas, with gender (OR 2.08; 95%CI: 1.30 to 3.34; I2 = 13%; p = 0.002) especially in non-Asian population, and higher in primary tumor than recurrent tumor (OR 4.31; 95%CI: 1.41 to 13.14; I2 = 13%; p = 0.01). On the prognostic value, SOX2 overexpression insignificantly associates with poor overall survival (HR 1.73; 95%CI: 0.49 to 6.18; I2 = 83%; p = 0.40)

Conclusion: SOX2 overexpression suggests a role as a biomarker in predicting the poorer grade of CNS tumors.


  1. Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep [Internet]. 2021;21(12). Available from:
  2. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406.
  3. Scheie D, Kufaishi HHA, Broholm H, Lund EL, de Stricker K, Melchior LC, et al. Biomarkers in tumors of the central nervous system – a review. Apmis. 2019;127(5):265–87.
  4. Daşdelen D, Demirezen A, Akdoğu BS, Altuntaş İ, Erbaş O. SOX2 Gene and Tumor Development. J Exp Basic Med Sci. 2021;2(3):318–25.
  5. Mansouri S, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD, et al. Sox2: regulation of expression and contribution to brain tumors. CNS Oncol. 2016 Jul;5(3):159–73.
  6. Abdelrahman AE, Ibrahim HM, Elsebai EA, Ismail EI, Elmesallamy W. The clinicopathological significance of CD133 and Sox2 in astrocytic glioma. Cancer Biomarkers. 2018;23(3):391–403.
  7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372.
  8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:1–16.
  9. Alamir H, Alomari M, Salwati AAA, Saka M, Bangash M, Baeesa S, et al. In situ characterization of stem cells-like biomarkers in meningiomas. Cancer Cell Int [Internet]. 2018;18(1):1–14. Available from:
  10. Berezovsky AD, Poisson LM, Cherba D, Webb CP, Transou AD, Lemke NW, et al. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia (United States) [Internet]. 2014;16(3):193-206.e25. Available from:
  11. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology. 2011 Oct;59(4):763–75.
  12. ASMAA Y. IBRAHIEM, M.Sc. SFMMD., AMR A. KAMEL, M.D. MAAMMD. Correlation between SOX2 and Mutant IDH1 Protein Expression in Astrocytomas and their Clinicopathologic Significance. Med J Cairo Univ. 2018;86(12):3893–903.
  13. Vasquez JC, Huttner A, Zhang L, Marks A, Chan A, Baehring JM, et al. SOX2 immunity and tissue resident memory in children and young adults with glioma. J Neurooncol. 2017 Aug;134(1):41–53.
  14. Wang B, Li M, Wu Z, Li X, Li Y, Shi X, et al. Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma. Exp Ther Med. 2015;10(1):88–96.
  15. Xiao Z-Y, Chen X-J, Pan Q, Yang Q-Z, Li K-Z. Expression of Nestin, CD133 and Sox2 in Meningiomas. Turk Neurosurg. 2018;28(6):910–4.
  16. Yu W, Ren X, Hu C, Tan Y, Shui Y, Chen Z, et al. Glioma SOX2 expression decreased after adjuvant therapy. BMC Cancer. 2019;19(1):1–9.
  17. Khan IN, Ullah N, Hussein D, Saini KS. Current and emerging biomarkers in tumors of the central nervous system: Possible diagnostic, prognostic and therapeutic applications. Semin Cancer Biol [Internet]. 2018;52:85–102. Available from:
  18. Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target. Signal Transduct Target Ther [Internet]. 2020;5(1). Available from:
  19. Zheng Y, Qin B, Li F, Xu S, Wang S, Li L. Clinicopathological significance of Sox2 expression in patients with breast cancer: A meta-analysis. Int J Clin Exp Med. 2015;8(12):22382–92.
  20. Goyal R, Spencer KA, Borodinsky LN. From Neural Tube Formation Through the Differentiation of Spinal Cord Neurons: Ion Channels in Action During Neural Development. Front Mol Neurosci. 2020;13(April):1–11.
  21. Niklison-Chirou MV, Agostini M, Amelio I, Melino G. Regulation of adult neurogenesis in mammalian brain. Int J Mol Sci. 2020;21(14):1–21.
  22. Grimm D, Bauer J, Wise P, Krüger M, Simonsen U, Wehland M, et al. The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol [Internet]. 2020;67:122–53. Available from:
  23. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics. 2011;8(3):139–47.
  24. Zhang X hui, Wang W, Wang Y qi, Zhu L, Ma L. The association of SOX2 with clinical features and prognosis in colorectal cancer: A meta-analysis. Pathol Res Pract [Internet]. 2020;216(1):152769. Available from:
  25. Galiakberova AA, Dashinimaev EB. Neural Stem Cells and Methods for Their Generation From Induced Pluripotent Stem Cells in vitro. Front Cell Dev Biol. 2020;8(October).
  26. Liu K, Lin B, Zhao M, Yang X, Chen M, Gao A, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal [Internet]. 2013;25(5):1264–71. Available from:
  27. Lopez-Bertoni H, Johnson A, Rui Y, Lal B, Sall S, Malloy M, et al. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduct Target Ther. 2022;7(1):1–12.
  28. Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi S reza, Hassanpoor A, Aboutalebi M, et al. SOX2 function in cancers: Association with growth, invasion, stemness and therapy response. Biomed Pharmacother [Internet]. 2022;156:113860. Available from:
  29. Gao H, Teng C, Huang W, Peng J, Wang C. SOX2 Promotes the Epithelial to Mesenchymal Transition of Esophageal Squamous Cells by Modulating Slug Expression through the Activation of STAT3/HIF-α Signaling. Int J Mol Sci. 2015 Sep;16(9):21643–57.
  30. Liu X, Qiao B, Zhao T, Hu F, Lam AK-Y, Tao Q. Sox2 promotes tumor aggressiveness and epithelial‑mesenchymal transition in tongue squamous cell carcinoma. Int J Mol Med. 2018 Sep;42(3):1418–26.
  31. Gao L, Liu J, Zhang S, Li Y, Tan Y, Yang J, et al. TMBIM1 Promotes EMT by Stimulating Autophagic Degradation of E-Cadherin via AMPK/mTOR/ULK1 Axis in Human Gliomas. SSRN Electron J. 2021;1–24.
  32. Liu P, Tang H, Song C, Wang J, Chen B, Huang X, et al. SOX2 promotes cell proliferation and metastasis in triple negative breast cancer. Front Pharmacol. 2018;9(AUG):1–8.
  33. Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One. 2013;8(8).
  34. Javaeed A, Ghauri SK. Metastatic potential and prognostic significance of SOX2: A meta-analysis. World J Clin Oncol. 2019;10(6):234–46.

How to Cite

Sasmana, I. G. A. P., Wiranata, S., Yogananda, K. C. ., Wihandani, D. M., & Supadmanaba, I. G. P. (2023). Clinicopathological and Prognostic Significance of SRY-Box Transcription Factor 2 (SOX2) Overexpression in Central Nervous System Tumor: A Meta-Analysis. Bali Medical Journal, 12(2), 1733–1739.




Search Panel

I Gede Aswin Parisya Sasmana
Google Scholar
BMJ Journal

Sinta Wiranata
Google Scholar
BMJ Journal

Komang Chandra Yogananda
Google Scholar
BMJ Journal

Desak Made Wihandani
Google Scholar
BMJ Journal

I Gede Putu Supadmanaba
Google Scholar
BMJ Journal